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Abstract
Background: Calprotectin (S100A8/A9 or MRP8/14) and S100A12 (leukocyte-derived proteins), interleukin 6 (IL-6)
and vascular endothelial growth factor (VEGF) are markers of inflammation and angiogenesis. Ultrasound (US) is
sensitive for detection of greyscale synovitis and power Doppler (PD) vascularization. The objective of the present
study was to explore the associations between calprotectin, S100A12, IL-6, VEGF, erythrocyte sedimentation rate,
C-reactive protein and a comprehensive US assessment in patients with rheumatoid arthritis (RA) starting biologic
disease-modifying anti-rheumatic drug (bDMARD) treatment.
Methods: A total of 141 patients with RA were assessed by US, clinical examination and biomarker levels at
baseline and at 1, 2, 3, 6 and 12 months after initiation of bDMARDs. US assessment of 36 joints and 4 tendon
sheaths were scored semi-quantitatively (0–3 scale). European League Against Rheumatism (EULAR) response was
calculated. Statistical assessments performed to explore the associations between biomarkers and US sum scores
included Spearman’s rank correlation analysis as well as linear and linear mixed model regression analyses.
Results: Calprotectin showed the overall strongest correlations with both US sum scores (rs = 0.25–0.62) and
swollen joint counts (of 32) (rs = 0.24–0.47) (p < 0.05 at all examinations). An association with US sum scores
remained after we adjusted for age, sex, disease duration and all the other markers in a regression analysis at
baseline. Decreased calprotectin at the first month was predictive of both EULAR response (p ≤ 0.001) and
decreased sum PD scores at 3, 6 and 12 months (p ≤ 0.05).
Conclusions: Calprotectin had the highest association with US synovitis and predicted treatment response.
It may thus be considered as a marker for evaluating inflammation and responsiveness in patients with RA on
bDMARD treatment.
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Background
Rheumatoid arthritis (RA) is an autoimmune disease
with a complex pathogenesis involving innate and adap-
tive immunity as well as angiogenesis [1, 2]. Biomarkers
can reflect these reactions and provide support in diag-
nostic and prognostic evaluations. Despite intensive re-
search, only C-reactive protein (CRP) and erythrocyte
sedimentation rate (ESR) are regularly used as inflamma-
tory biomarkers in the clinics.
Calprotectin is a heterocomplex of the S100 proteins
S100A8 and S100A9 (also called myeloid-related protein
8 [MRP8] and MRP14), found mainly in circulating neu-
trophils and monocytes and in macrophages in RA syn-
ovial tissue [3, 4]. Up to 60% of the cytosolic protein
content in granulocytes is reported to be calprotectin
[5]. S100A12 is another inflammation-associated S100
protein, expressed predominantly in neutrophils and
comprising about 5% of the protein content in the cyto-
sol [6]. Calprotectin and S100A12 are pro-inflammatory
proteins. By their putative binding to Toll-like receptor
4 or receptor for advanced glycation endproducts on
granulocytes, monocytes, or endothelial cells, the S100
proteins have the potential to induce production of im-
portant cytokines in RA, such as interleukin (IL)-1β, IL-
6 and tumour necrosis factor, as well as intracellular and
vascular cell adhesion molecules, via the nuclear factor-
κB pathway [7]. In addition, calprotectin and S100A12
can be chemoattractants for neutrophils and monocytes/
mast cells, respectively [7] and can thus in several ways
contribute to recruitment of leukocytes to inflammatory
sites. Both proteins have, when measured in plasma or
serum, been repeatedly reported to be associated with
clinical disease activity in RA [8–18]. In addition, calpro-
tectin was associated with radiographic damage in a
cross-sectional study and predicted radiographic pro-
gression in a longitudinal study [11, 19], whereas
S100A12 has shown a weak association with radio-
graphic damage in a small longitudinal study [17].
IL-6 is a cytokine that stimulates hepatocytes (produc-
tion of CRP and other acute-phase proteins), B cells
(maturation, antibody production), T cells (Th17 differ-
entiation), neutrophils (activation and migration), osteo-
clasts (maturation) and vascular endothelial growth
factor (VEGF) [20]. IL-6 has been associated with dis-
ease activity and radiographic progression [21]. VEGF is
an important inducer of angiogenesis as well as a
vascular permeability factor [2]. It was found to be asso-
ciated with disease activity [22, 23] and with radio-
graphic destruction in patients with RA [24].
Ultrasound (US) is a sensitive and validated imaging
technique for evaluation of synovitis in patients with
RA [25]. The inflammation is usually scored semi-
quantitatively for both the amount of synovitis (greyscale
[GS]) and the degree of vascularization (power Doppler
[PD]). High reliability has been demonstrated for scoring
of synovitis of a large number of joints in patients with
RA by use of a US atlas as a reference [26].
To date, there have been two small longitudinal stud-
ies and two small cross-sectional studies on the correla-
tions between the two S100 proteins and US findings
[16, 27–29]. IL-6 has been shown to have significant cor-
relations with US synovitis in cross-sectional studies of
early disease-modifying anti-rheumatic drug (DMARD)-
naïve patients with RA [30] and with PD score in pa-
tients with established RA treated with non-biologic
DMARDs [31], respectively. Being a marker of angiogen-
esis, VEGF may be associated with Doppler activity in
inflamed RA joints. However, so far, there is no agree-
ment on the association between VEGF and PD [32–38].
Markers such as ESR and CRP are frequently used but
may not always reflect the ongoing synovitis. Thus, there
is a need for new biomarkers that have stronger associa-
tions with inflammation and angiogenesis in patients
with RA. The main objective of the present study was to
explore associations between inflammatory/angiogenic
markers (calprotectin, S100A12, IL-6 and VEGF) and a
comprehensive US examination, as well as clinical
assessments, in a longitudinal study of patients with
established RA starting biologic disease-modifying anti-
rheumatic drug (bDMARD) treatment.
Methods
Patients and control subjects
A total of 141 patients with RA, all meeting the 1987 re-
vised American Rheumatism Association classification
criteria [39], were consecutively included at an out-
patient rheumatology clinic in the period from January
2010 to June 2013 when starting a bDMARD. A total of
45.4% started with their first bDMARD, 30.5% with their
second bDMARD, and 24.1% had used up to three to
five bDMARDs previously. All patients continued their
bDMARD during the study, and they were assessed at
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baseline and at 1, 2, 3, 6 and 12 months. Age- and sex-
matched healthy control subjects (blood donors)
recruited from Haukeland University Hospital, repre-
senting the same ethnic origin as the patients, were in-
cluded for obtaining normal levels of S100A12, IL-6 and
VEGF in serum (Table 1), whereas normal levels of cal-
protectin in ethylenediaminetetraacetic acid (EDTA)
plasma were given by the manufacturer CALPRO AS,
Lysaker, Norway (based on levels from blood donors at
Ullevål University Hospital).
Clinical disease activity
The 28-joint examination of tender and swollen joints
[40], with the addition of bilateral ankle and metatarso-
phalangeal (MTP) joints 1–5 (the MTP joints evaluated
as one joint) (i.e., a total of 32 joints), was performed by
two trained and experienced study nurses blinded to the
US results. The assessor’s (study nurse’s) global evalu-
ation of disease activity, as well as the patient’s global as-
sessment of disease activity and pain, were recorded on
0- to 100-mm visual analogue scales. The Disease Activ-
ity Score in 28 joints including ESR (DAS28) [40] was
calculated, and improvement of disease activity from
baseline was recorded according to the European League
Against Rheumatism (EULAR) response criteria [41].
Ultrasound
An experienced sonographer (HBH) performed all the
US examinations (using an Antares Excellence version
5- to 13-MHz probe [Siemens Healthcare, Erlangen,
Germany], optimized for PD with pulse repetition fre-
quency 391 Hz, and no updates during the study) and
had no access to the clinical assessments and biomarkers
from the same time point or to previous US results. GS
and PD were scored semi-quantitatively on a 4-point
scale (0 = no, 1 =minor, 2 =moderate, 3 =major pres-
ence) of 36 joints (bilateral wrist, comprising radiocarpal
[RC], midcarpal [MC] and radioulnar [RU] joints; meta-
carpophalangeal [MCP] joints 1–5; proximal interpha-
langeal (PIP) joints 2 and 3; elbow; knee; ankle
[tibiotalar]; and MTP1–5) and 4 tendon sheaths (exten-
sor carpi ulnaris [ECU] and tibialis posterior [TP]) [26].
The size of the joint may influence the burden of syno-
vitis. Thus, weighting of joints according to the method
of Lansbury [42] was also included when exploring asso-
ciations. (US scores of MCP, PIP and MTP joints were
multiplied by 1; RC, MC and RU joints were multiplied
by 2; ECU and TP sheaths were multiplied by 2; elbow
was multiplied by 12; knee was multiplied by 25; and the
ankle was multiplied by 9.)
Assessment of biomarkers
Rheumatoid factor, anti-cyclic citrullinated peptides, CRP
and ESR were analysed by routine in-house methodology.
The samples were treated as uniformly as possible, centri-
fuged within 1 h after sampling, and plasma/serum was
removed and put in the freezer as soon as possible and
carefully thawed in a refrigerator overnight before the ana-
lysis. All samples from the same patient (and respective
control subject) were thawed at the same time for the ana-
lyses of the biomarkers. Laboratory personnel (KAB, MS
and HHN) were blinded to the results of the clinical, US
and laboratory assessments. Calprotectin was analysed in
EDTA-plasma by a commercial enzyme-linked immuno-
sorbent assay (ELISA) (CALPRO AS, Lysaker, Norway),






Age, years 54 (45–61) 54 (45–61) 0.96
Women 114 (80.9) 114 (80.9) 1.0
Disease duration, years 6.8 (3.0–14.9)
RF-positive 100 (70.9)
Anti-CCP-positive 109 (77.3)
Using methotrexate 109 (77.3)
Using prednisolone 78 (55.3)









Patient’s global VAS, 0–100 46 (20–67)
Assessor’s global VAS, 0–100 27 (18–38)
Number of tender joints (of 32) 4 (2–11)
Number of swollen joints (of 32) 6 (3–11)
DAS28(ESR) 4.4 (1.4)a
Sum GS US score 27 (17–43)
Sum PD US score 11 (4–24)
ESR, mm/h 22 (11–35)
CRP, mg/L 6 (2–12)
Calprotectin, ng/ml 1149 (698–1949) 560 (412–796)b <0.001
S100A12, ng/ml 275 (142–463) 129 (75–222) <0.001
IL-6, pg/ml 5.2 (2.1–10.8) 0.9 (0.2–1.6) <0.001
VEGF, pg/ml 80.8 (42.8–161.8) 67.5 (45.6–108.0) <0.08
Abbreviations: RF Rheumatoid factor, anti-CCP Anti-cyclic citrullinated peptide,
DMARD Disease-modifying anti-rheumatic drug, VAS Visual analogue scale,
DAS28 Disease Activity Score in 28 joints, ESR Erythrocyte sedimentation rate,
GS Greyscale, US Ultrasound, PD Power Doppler, VEGF Vascular endothelial
growth factor, IL-6 Interleukin 6
Data are median (interquartile range) for continuous variables and number
(percent) for categorical variables
aMean (±SD)
bControl subjects are healthy blood donors (50 men and 50 women) analysed
by the manufacturer CALPRO AS, Lysaker, Norway
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and S100A12 was analysed in serum by ELISA (CycLex
Co., Nagano, Japan), both according to the instructions of
the manufacturers. The plates were read by an Emax plate
reader with Softmax Pro software version 5.4 (Molecular
Devices, Sunnyvale, CA, USA). IL-6 and VEGF were ana-
lysed in serum by a premixed multi-analyte kit (R&D Sys-
tems, Minneapolis, MN, USA), following the instructions
of the manufacturer, and the plates were read on a Lumi-
nex 100 system (Luminex Corp., Austin, TX, USA) with
use of STarStation version 3.0 software (Applied Cytome-
try Systems, Dinnington, UK).
Statistics
The Mann-Whitney U test or the Wilcoxon signed-rank
test was used to evaluate differences between and within
groups and to study changes from baseline, respectively.
Correlations were explored by Spearman’s rank correl-
ation analyses. Linear regression was used for further
studies of associations. In a first step, we adjusted for
age, sex and disease duration, and then all the markers
were included in a second step. To predict change in US
sum scores, a linear mixed model regression analysis
was used. All markers had right-skewed distributions
and were log2-transformed prior to inclusion in the re-
gression models. IBM SPSS Statistics version 23 (IBM,
Armonk, NY, USA), R version 3.2.3 for Windows
(http://www.r-project.org) and Prism version 5 (Graph-
Pad Software, La Jolla, CA, USA) software were used for
the statistical analyses and to create figures. All tests for
significance were two-sided, and p < 0.05 was considered
significant. Plasma/serum samples or clinical data were
not available for 31 (3.7%) of 846 examination time
points. The missing data were replaced by the last obser-
vation carried forward.
Results
Baseline levels of calprotectin, S100A12 and IL-6 were
significantly higher in patients than in control subjects,
but this was not shown for VEGF (Table 1). DAS28, the
US sum scores and all the biomarkers (except IL-6)
decreased significantly from baseline (Fig. 1). How-
ever, IL-6 was significantly elevated after baseline in
sera of patients starting with tocilizumab (n = 12,
8.5%) (Additional file 1: Figure S1). When the patients
on tocilizumab were omitted from the calculation, IL-
6 showed a significant decrease (p < 0.001) from base-
line at all time points, except at 2 months (p = 0.06)
(results not shown).
Of the biomarkers, calprotectin had the strongest and
most consistent associations with clinical variables and
US sum scores in correlation analyses at baseline
(Table 2), and there were comparable correlation coeffi-
cients during follow-up (Additional file 2: Table S1). We
also analysed the two largest subgroups of patients on
bDMARDs (i.e., etanercept [n = 56] and rituximab [n = 32]).
Calprotectin was the marker most strongly associated with
US sum scores in these subgroups. In patients on etaner-
cept, calprotectin had median (range) correlation coeffi-
cients of 0.46 (0.13–0.52) with GS sum score and 0.43
(0.15–0.58) with PD sum score (p = ns to <0.001). In rituxi-
mab users, calprotectin had correlation coefficients of 0.58
(0.39–0.73) with GS sum score and 0.53 (0.41–0.70) with
PD sum score (p = 0.03 to <0.001). The correlations be-
tween calprotectin and US sum scores weighted according
to the method of Lansbury were not much different
from, and not consistently stronger than, correlations
between calprotectin and the original US sum scores
(Additional file 3: Table S2). Patients on tocilizumab
(n = 12, 8.5%) had overall higher correlations between
calprotectin and US sum scores compared with ESR
and CRP during follow-up, although these correlations
were not always significant (Additional file 4: Table S3).
Cross-sectional linear regression analysis at baseline is
presented in Fig. 2. Calprotectin could best explain the
US scores after adjusting for age, sex and disease dur-
ation, as well as after additional adjustment for all the
other markers.
The influence of prednisolone use was explored by
assessing differences between patients using or not
using prednisolone at baseline. Patients on prednisol-
one at baseline (n = 78 [55.3%], median [range] dose 7.5
[2.5–25] mg) had higher levels of calprotectin (p = 0.006),
GS sum score (p = 0.02) and number of swollen joints
(p = 0.02), whereas no differences were found between
the groups for any of the other markers or clinical
variables.
To explore whether the biomarkers had normal
levels in patients without active synovitis, we analysed
the biomarkers in patients with a PD sum score of 0
after 12 months (n = 30) and compared them with the
levels found in healthy control subjects (Additional
file 5: Figure S2). For calprotectin, S100A12 and
VEGF, there was no difference between the patients
and the control subjects, whereas IL-6 was higher in
the patients (although patients on tocilizumab were
excluded).
Changes (Δ) in the biomarkers were calculated as the
differences from baseline to 1, 2, 3, 6 and 12 months.
Except for the association between ΔESR and ΔDAS28,
Δcalprotectin had the overall strongest associations with
the corresponding changes in US sum scores and
DAS28 (Additional file 6: Table S4).
The median (interquartile range) levels of the bio-
markers in EULAR good, moderate and non-responders
at 3, 6 and 12 months are shown in Additional file 7:
Table S5. The largest differences between the groups
were found for ESR and CRP. EULAR responders
(good and moderate) at 3 months had significantly
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Table 2 Spearman’s rank correlation coefficients between biomarkers and ultrasound sum scores and clinical parameters at baseline




Patient’s global VAS Joint pain VAS
Calprotectin 0.59a 0.62a 0.60a 0.49a 0.47a 0.17b 0.27a 0.32a
S100A12 0.39a 0.42a 0.44a 0.35a 0.35a 0.14 0.22b 0.23b
IL-6 0.42a 0.49a 0.53a 0.39a 0.41a 0.09 0.20b 0.24b
VEGF 0.20b 0.18b 0.14 0.10 0.13 −0.03 0.15 0.21b
ESR 0.19b 0.30a 0.46a 0.67a 0.22b 0.27a 0.28a 0.33a
CRP 0.41a 0.47a 0.46a 0.47a 0.30a 0.15 0.18b 0.24b
Abbreviations: Sum GS score Sum of greyscale scores on a 0–3 scale of 36 joints and four tendon sheaths, Sum PD score Sum power Doppler scores on a 0–3 scale
of 36 joints and 4 tendon sheaths, VAS Visual analogue scale, DAS28 Disease Activity Score in 28 joints (including erythrocyte sedimentation rate), VEGF Vascular
endothelial growth factor, IL-6 Interleukin 6, ESR Erythrocyte sedimentation rate, CRP C-reactive protein
ap < 0.05
bp ≤ 0.001
Fig. 1 Median levels (error bars = interquartile range) of inflammatory markers, Disease Activity Score in 28 joints (DAS28) and ultrasound sum
score (greyscale [GS] and power Doppler [PD]) at baseline and during follow-up. * p < 0.05, ** p < 0.001 reduction from baseline. CRP C-reactive
protein, ESR Erythrocyte sedimentation rate, VEGF Vascular endothelial growth factor
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higher baseline values of calprotectin (p = 0.001),
S100A12 (p = 0.02), IL-6 (p = 0.02) and CRP (p = 0.003)
than non-responders. Although calprotectin showed a
trend (p = 0.08), EULAR responders at 6 months did
not have significantly higher values of any of the
markers at baseline. For EULAR responders after
12 months, only calprotectin (p = 0.03) had significantly
higher baseline values. In addition, EULAR responders
recorded at 3-, 6- and 12-month follow-up had
significantly higher Δcalprotectin during the first
month (p ≤ 0.001 for all time points), whereas such a
strong difference was not found for the other markers.
(ESR was not included in this calculation, because it is
a part of the EULAR response criteria.)
In the linear mixed model analysis, there was a trend
for Δcalprotectin during the first month to predict
change in GS sum scores after 3 months (p = 0.09).
However, significant prediction was found after 6 months
(p = 0.03) but not after 12 months (p = 0.20). ΔESR did
not predict change in GS sum scores, whereas ΔCRP
predicted change in GS sum scores after 12 months
(p = 0.01). ΔCalprotectin during the first month pre-
dicted change in PD sum scores at 3, 6 and 12 months
(p = 0.05, 0.004 and 0.002, respectively). ΔESR also
predicted change in PD sum scores at 3, 6 and
12 months (p = 0.01, 0.01 and <0.001, respectively),
whereas ΔCRP was predictive of change in PD sum score
at 6 months (p = 0.03) and 12 months (p < 0.001).
Fig. 2 Linear regression model, baseline. Coefficients with 95% confidence intervals with (a) greyscale sum score and (b) power Doppler sum score as
dependant variables. IL-6 Interleukin 6, CRP C-reactive protein, ESR Erythrocyte sedimentation rate, VEGF Vascular endothelial growth factor
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ΔS100A12, ΔVEGF and ΔIL-6 did not significantly predict
change in GS or PD sum scores.
Discussion
In this 1-year follow-up study of 141 patients with RA
starting bDMARDs, we found calprotectin to be more
strongly associated with US and clinical scores of inflam-
mation than ESR, CRP, S100A12, IL-6 and VEGF. In
addition, a higher level of calprotectin was found in
EULAR responders, and decrease of calprotectin during
the first month predicted reduced PD sum scores at 3, 6
and 12 months.
The present study supports the previous finding of
strong associations between calprotectin and US sum
scores in a small longitudinal study [27] and two small
cross-sectional studies [28, 29]. The association is likely
due to calprotectin being found in leukocytes, and, with
its impact on immune cells and endothelial cells in the
joints, calprotectin may have the ability to reflect the US
findings of inflammation. This is also supported by the
finding of normal levels of calprotectin in patients with
no sign of PD activity, which is in agreement with a re-
cent study in which calprotectin could help identify PD
synovitis in patients with DAS28 ≤ 3.2 [29].
There are conflicting results on baseline calprotectin as
a predictive marker of response to bDMARDs [13, 17, 43].
High levels of biomarkers at baseline imply a large poten-
tial for improvement but might not consistently predict
response to treatment. Calprotectin showed a rapid de-
crease during bDMARD treatment, and Δcalprotectin
after 1 month predicted EULAR response. In addition, cal-
protectin and ESR were the only biomarkers where change
during the first month predicted change in PD sum scores.
Thus, calprotectin may have a potential for early predic-
tion of response to bDMARD treatment. ΔCalprotectin
during the first month was more predictive of change in
PD sum score than change in GS sum score. This might
be explained by PD detecting arterioles dilated because of
chemical and inflammatory mediators locally in the area of
synovitis. PD activity is found to diminish rapidly after
glucocorticoid injection in a joint, and this is thought to be
caused by a reduction of inflammatory mediators causing
the arterioles not to be dilated [44], even if they are still
present in the synovium. Thus, on one hand, calprotectin
may be associated with, and may predict, the PD activity
because both calprotectin and PD are reflecting inflamma-
tion. The GS findings, on the other hand, represent syno-
vium that may be more or less actively inflamed and may
therefore not have the same association with inflammatory
markers. As a parallel, in inflammatory bowel diseases,
calprotectin levels (in faeces) have been shown to be asso-
ciated with inflammation and found to be highly useful in
the clinics by predicting clinical response and mucosal
healing in patients treated with biologics [45].
Tocilizumab suppresses the conventional inflamma-
tory markers. Only a small number of patients used toci-
lizumab in this study. However, calprotectin was shown
to have stronger associations with the US scores than
ESR and CRP in these patients. This is supported by a
study of 33 patients with RA treated with tocilizumab in
whom calprotectin had stronger correlations with com-
posite scores (DAS28, Simplified Disease Activity Index
and Clinical Disease Activity Index) and joint counts
compared with CRP and ESR [46].
Prednisolone may decrease inflammatory markers, but
use of prednisolone did not seem to suppress the levels
of calprotectin, supporting the results of a previous
study [11]. Thus, in patients on prednisolone, the in-
flammatory activity in established RA may be better
reflected by calprotectin than by the commonly used
ESR and CRP.
Associations of S100A12 with clinical variables and US
scores were comparable with those of CRP, but lower
than for calprotectin. The explanation for the two S100
proteins’ having different reflection of inflammation
could in part be the differences in their distribution and
amounts in leukocytes. PD may reflect the angiogenesis,
and S100A12 is particularly found in perivascular neu-
trophils of RA synovia [47] and is able to activate endo-
thelial cells [7]. We previously reported associations
between S100A12 and PD in a small longitudinal study
[16], and the results of the present study strengthen this
preliminary finding by showing consistent associations
at all time points.
IL-6 was a relatively strong marker of inflammation
in this study, probably reflecting its key functions in
RA [1, 20]. This is in agreement with previous studies
[21, 30, 31]. However, IL-6 levels increase during toci-
lizumab treatment [48], which was also shown in this
study (Additional file 1: Figure S1).
VEGF had the weakest associations with US and clin-
ical variables in the present study. This angiogenic
marker was expected to be associated with PD scores.
However, there were low correlations between VEGF
and PD sum scores. Previous studies have diverged in
designs and results [32–38]. Only small groups of pa-
tients were included (15–29 patients) in most of the pre-
vious studies on VEGF, and different numbers of joints
have been assessed (PD in 1–22 joints). In addition, all
but one study had a cross-sectional design. Thus, the
present large longitudinal study, in which we examined a
high number of joints, supports previous studies indicat-
ing that VEGF is not a strong marker of active synovitis
in patients with RA.
The present study has several strengths. A large num-
ber of patients with RA were included; they were
assessed six times during 1 year after initiation of treat-
ment with bDMARDs; and the comprehensive US
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examination was performed by one experienced sonog-
rapher. The study was carried out in a regular clinical
setting, which may support the external validity of the
findings. A limitation may be the relatively low disease ac-
tivity in spite of including only patients starting a
bDMARD, which could have had an impact on the re-
sponsiveness of the inflammatory markers. A high number
of joints were examined by US, but the inclusion of even
more joints might possibly have influenced the results.
Weighting of joints in accordance with the Lansbury
method did not increase the correlation between US
scores and calprotectin. Whether another form of weight-
ing of joints would increase the associations between
calprotectin and US pathology remains to be explored.
Conclusions
Calprotectin was found to be the biomarker with the
strongest associations with both US and clinical disease
activity assessments during 1 year of follow-up among
patients with established RA starting bDMARDs. In
addition, reduction of calprotectin after 1 month was
predictive of EULAR response and decrease in PD sum
scores. Thus, we suggest that calprotectin measured in
EDTA-plasma could be a valuable supplement to the
conventional inflammatory markers when assessing pa-
tients with RA during follow-up of bDMARD treatment.
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